Page 223 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation
P. 223
Optimal timing and response criteria of Interim-PET in DLBCL
Figure 5. Two-year PFS Cox regression stratified for ∆SUVmax I-PET-positive patients and timing. Corrected for low-risk (A), low-intermediate risk (B), high-intermediate risk (C), and high-risk (D)
IPI groups.
This study had several strengths. By collecting individual patient data from high- quality studies that performed an I-PET at multiple time points and by collecting both DS and ∆SUVmax data, our analysis enabled us to determine the optimal timing and make firmer conclusions on optimal criteria for I-PET in DLBCL. Furthermore, survival data were harmonized by re-calculating the follow-up between original studies. All available I-PETs without DS or ∆SUVmax data were re-reviewed. The lack of standardization between I-PET response criteria was overcome by re-classifying DS5 patients on a semi-quantitative basis. This recalculation of variables in the PETRA database allowed for a statistically more
221
8
